BlackRock Inc. lifted its stake in shares of argenx SE (NASDAQ:ARGX – Get Rating) by 2.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 804,719 shares of the company’s stock after acquiring an additional 18,092 shares during the quarter. BlackRock Inc. owned about 1.45% of argenx worth $284,106,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its stake in shares of argenx by 3.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 6,377,316 shares of the company’s stock valued at $2,416,237,000 after acquiring an additional 182,835 shares during the period. FMR LLC grew its position in argenx by 6.3% in the second quarter. FMR LLC now owns 4,974,343 shares of the company’s stock worth $1,884,680,000 after buying an additional 294,228 shares during the last quarter. Capital World Investors grew its position in argenx by 12.0% in the first quarter. Capital World Investors now owns 739,392 shares of the company’s stock worth $233,138,000 after buying an additional 79,119 shares during the last quarter. Pictet Asset Management SA grew its position in argenx by 10.5% in the second quarter. Pictet Asset Management SA now owns 569,502 shares of the company’s stock worth $215,773,000 after buying an additional 53,958 shares during the last quarter. Finally, RTW Investments LP grew its position in argenx by 5.5% in the third quarter. RTW Investments LP now owns 467,195 shares of the company’s stock worth $164,943,000 after buying an additional 24,560 shares during the last quarter. Institutional investors and hedge funds own 57.29% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have issued reports on ARGX shares. Barclays lifted their price target on shares of argenx from €405.00 ($430.85) to €450.00 ($478.72) and gave the stock an “overweight” rating in a research report on Tuesday, December 6th. HC Wainwright restated a “buy” rating and issued a $480.00 price target on shares of argenx in a research report on Friday, March 3rd. JPMorgan Chase & Co. lifted their price target on shares of argenx from €470.00 ($500.00) to €480.00 ($510.64) and gave the stock an “overweight” rating in a research report on Monday, November 14th. Cowen lifted their price target on shares of argenx from $441.00 to $458.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 25th. Finally, JMP Securities raised their price objective on shares of argenx from $443.00 to $448.00 and gave the stock a “market outperform” rating in a research note on Friday, March 3rd. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $454.50.
argenx Stock Down 0.0 %
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.